Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment (Alzheimer's Research & Therapy, (2023), 15, 1, (117), 10.1186/s13195-023-01253-2)

Patricia Diaz‑Galvan, Giulia Lorenzon, Rosaleena Mohanty, Gustav Mårtensson, Enrica Cavedo, Simone Lista, Andrea Vergallo, Kejal Kantarci, Harald Hampel, Bruno Dubois, Michel J. Grothe, Daniel Ferreira, Eric Westman

Research output: Contribution to journalComment/debatepeer-review

Abstract

Following publication of the original article [1], the authors identified an error to the titles and labels of axes in Figs. 3 and 4, as well as the captions of treatment groups on Fig. 4. This error does not affect the accuracy and clarity of the research presented, neither does affect the interpretation of the results. The corrected figures are given below. In Fig. 3A (Scatterplot of the hippocampus-to-cortex ratio by BV/CSF index), labels indicating the MRI subtypes are in the reverse order. In the X axis, which corresponds to the “TYPICALITY-Hippocampus-to-cortex ratio”, labels should go from “Limbic-predominant” (on the left) to “Hippocampal-sparing” (on the right). In the Y axis, which corresponds to the “SEVERITY-BV:CSF index”, labels should go from “Minimal atrophy” (at the top) to “Typical AD” (at the bottom). In the X axis, which corresponds to the “TYPICALITY-Hippocampus-to-cortex ratio”, labels should go from “Limbic-predominant” (on the left) to “Hippocampal-sparing” (on the right). In the Y axis, which corresponds to the “SEVERITY-BV:CSF index”, labels should go from “Minimal atrophy” (at the top) to “Typical AD” (at the bottom). In Fig. 4 (interaction plots between severity/typicality subtyping dimension and treatment in the MRI efficacy measures), captions of the lines indicating the treatment groups are in reversed order. Red lines correspond to the placebo group (not to the donepezil group), and blue lines correspond to the donepezil group (not to the placebo group). In Fig. 4C (interaction plot between typicality subtyping dimension and APC of lateral ventricle volume), axes titles are incorrect. X axis title should be “TYPICALITY-Hippocampus-to-cortex ratio”, instead of “SEVERITY-BV:CSF index”. Y axis title should be “APC Lateral Ventricle vol”, instead of "APC AD Signature cortical thickness”. Labels on the Y axis are also incorrect. They should be changed to “Increased atrophy rate” (at the top) and “Reduced atrophy rate” (at the bottom). X axis title should be “TYPICALITY-Hippocampus-to-cortex ratio”, instead of “SEVERITY-BV:CSF index”. Y axis title should be “APC Lateral Ventricle vol”, instead of "APC AD Signature cortical thickness”. Labels on the Y axis are also incorrect. They should be changed to “Increased atrophy rate” (at the top) and “Reduced atrophy rate” (at the bottom). Baseline MRI patterns characterized on continuous scales of subtyping dimensions. A Scatterplot of the hippocampus-to-cortex ratio (typicality subtyping dimension) by BV/CSF index (severity subtyping dimension). B Classification of MCI individuals according to the degree of global brain atrophy after applying clinical cut-offs on BV/CSF index (severity subtyping dimension). Note: BV = brain volume; CSF = cerebrospinal fluid Interaction plots between severity/typicality subtyping dimensions (X axis) and treatment (Y axis) in APC of AD signature cortical thickness which includes entorhinal, inferior temporal, middle temporal, and fusiform gyri thickness (A, B) and APC of lateral ventricle volume (C) The original article [1] has been updated.

Original languageEnglish (US)
Article number177
JournalAlzheimer's Research and Therapy
Volume15
Issue number1
DOIs
StatePublished - Dec 2023

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Fingerprint

Dive into the research topics of 'Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment (Alzheimer's Research & Therapy, (2023), 15, 1, (117), 10.1186/s13195-023-01253-2)'. Together they form a unique fingerprint.

Cite this